波呋莫司汀 | 55102-44-8

• 物质功能分类: 原料药 - 抗肿瘤药 - 烷化剂类抗肿瘤药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 波呋莫司汀
• 英文名称: (chloro-2-ethyl)-3-nitrosocarbamyl-3-1', O-isopropylidene-2',3', O-p-nitrobenzoyl-5', α,β-D-ribofurannose
• 英文别名: Bofumustine；[(3aR,6R,6aR)-4-[[2-chloroethyl(nitroso)carbamoyl]amino]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl 4-nitrobenzoate
• CAS: 55102-44-8
• 化学式: C₁₈H₂₁ClN₄O₉
• 分子量: 472.839
• InChiKey: YASNUXZKZNVXIS-CBNXCZCTSA-N

物化性质

• 熔点：
  101.5°C
• 沸点：
  124.5°C (rough estimate)
• 密度：
  1.4868 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  162
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2,3-O-isopropylidene-D-ribofuranosylamine toluene-p-sulphonate 、 4-硝基苯甲酰氯 、 N-(chloro-2-ethyl)-N-nitrosocarbamate du trichloro-2,4,5 thiophenol 在 N,N-二异丙基乙胺 作用下， 生成 波呋莫司汀
  参考文献：
  名称：

  Montero; Leydet; Messiez-Munoz, European Journal of Medicinal Chemistry, 1984, vol. 19, # 6, p. 512 - 518

  摘要：

  DOI：

文献信息

• MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS
  申请人：Abbott Laboratories

  公开号：US20160220739A1

  公开（公告）日：2016-08-04

  A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to drugs of Formula (I). The drugs of Formula (I) can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

  一种医疗器械包括一个支撑结构，该支撑结构能够容纳或支撑一种药学上可接受的载体或赋形剂，该载体或赋形剂可以含有一个或多个治疗剂或物质，其中载体最好在其表面包含一层涂层，该涂层含有治疗物质，例如药物。适用于本发明的医疗器械的支撑结构包括但不限于冠状动脉支架、外周支架、导管、动静脉移植物、旁路移植物和用于血管系统的药物输送球。适用于本发明的药物包括但不限于公式（I）中的药物。公式（I）中的药物可以与另一种药物结合使用，包括从抗增殖剂、抗血小板剂、抗炎剂、抗血栓剂、细胞毒性药物、抑制细胞因子或趋化因子结合的药物、细胞去分化抑制剂、降脂药、基质金属蛋白酶抑制剂、细胞周期停滞药或这些药物的组合中选择的药物。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS
  申请人：Viswanath Shekhar

  公开号：US20080085880A1

  公开（公告）日：2008-04-10

  A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof:

  一种雷帕霉素类似物组合物包括一个雷帕霉素类似物的晶体形式。该晶体可以是水合物、脱水物、溶剂物或脱溶剂物。雷帕霉素类似物可以具有公式1的结构，该结构可以是选择性的前药、盐、衍生物或其组合：
• METHODS OF MANUFACTURING CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS
  申请人：Viswanath Shekhar

  公开号：US20080091008A1

  公开（公告）日：2008-04-17

  A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.

  一种制备结晶性雷帕霉素类似物的方法包括：将雷帕霉素类似物与有机介质混合形成混合物；孵育混合物直到雷帕霉素类似物结晶；并回收结晶性雷帕霉素类似物。有机介质可以是溶剂，该过程可以包括使雷帕霉素类似物溶解到溶剂中，并孵育溶剂直到雷帕霉素类似物结晶。还可以进行以下操作：形成结晶性雷帕霉素类似物的浆料；搅拌雷帕霉素类似物混合物直到雷帕霉素类似物结晶；饱和雷帕霉素类似物溶液；形成过饱和雷帕霉素类似物溶液；将抗溶剂与雷帕霉素类似物和溶剂混合形成两相混合物，并孵育两相混合物以引起液液相分离。
• Methods of Manufacturing Crystalline Forms of Rapamycin Analogs
  申请人：VISWANATH Shekhar

  公开号：US20120028908A1

  公开（公告）日：2012-02-02

  A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.

  制备晶体雷帕霉素类似物的过程包括：将雷帕霉素类似物与有机介质混合形成混合物；孵育混合物直到雷帕霉素类似物结晶；并回收晶体雷帕霉素类似物。有机介质可以是溶剂，该过程可以包括使雷帕霉素类似物溶解到溶剂中，并孵育溶剂直到雷帕霉素类似物结晶。还可以进行以下操作：形成晶体雷帕霉素类似物的混浊液；搅拌雷帕霉素类似物混合物直到雷帕霉素类似物结晶；饱和雷帕霉素类似物溶液；形成过饱和雷帕霉素类似物溶液；将反溶剂与雷帕霉素类似物和溶剂混合形成两相混合物，并孵育两相混合物以引起液液相分离。